tradingkey.logo
tradingkey.logo
Pesquisar

Glaukos Corp

GKOS
Adicionar à lista de desejos
144.420USD
0.0000.00%
Fechamento 06/26, 16:00ETCotações atrasadas em 15 min
8.43BValor de mercado
PerdaP/L TTM

Mais detalhes de Glaukos Corp Empresa

Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; and bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders, among others.

Informações de Glaukos Corp

Código da empresaGKOS
Nome da EmpresaGlaukos Corp
Data de listagemJun 25, 2015
CEOBurns (Thomas William)
Número de funcionários995
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 25
Endereço1 Glaukos Way
CidadeALISO VIEJO
Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE
PaísUnited States of America
Código postal92656
Telefone19493679600
Sitehttps://www.glaukos.com
Código da empresaGKOS
Data de listagemJun 25, 2015
CEOBurns (Thomas William)

Executivos da empresa Glaukos Corp

Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Thomas William Burns
Mr. Thomas William Burns
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.70M
+4.98%
Mr. David F. Hoffmeister
Mr. David F. Hoffmeister
Independent Director
Independent Director
86.97K
+19.41%
Mr. Mark J. Foley
Mr. Mark J. Foley
Lead Independent Director
Lead Independent Director
59.10K
+3.18%
Ms. Aimee S. Weisner, J.D.
Ms. Aimee S. Weisner, J.D.
Independent Director
Independent Director
51.57K
+3.64%
Dr. Tomas Navratil
Dr. Tomas Navratil
Chief Development Officer
Chief Development Officer
49.04K
-3.13%
Mr. Marc A. Stapley
Mr. Marc A. Stapley
Independent Director
Independent Director
38.60K
+4.87%
Dr. Gilbert H. (Gil) Kliman, M.D.
Dr. Gilbert H. (Gil) Kliman, M.D.
Independent Director
Independent Director
--
--
Mr. Joseph E. Gilliam
Mr. Joseph E. Gilliam
President, Chief Operating Officer
President, Chief Operating Officer
--
--
Dr. Leana S. Wen, M.D.
Dr. Leana S. Wen, M.D.
Independent Director
Independent Director
--
--
Ms. Denice M. Torres, J.D.
Ms. Denice M. Torres, J.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Thomas William Burns
Mr. Thomas William Burns
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.70M
+4.98%
Mr. David F. Hoffmeister
Mr. David F. Hoffmeister
Independent Director
Independent Director
86.97K
+19.41%
Mr. Mark J. Foley
Mr. Mark J. Foley
Lead Independent Director
Lead Independent Director
59.10K
+3.18%
Ms. Aimee S. Weisner, J.D.
Ms. Aimee S. Weisner, J.D.
Independent Director
Independent Director
51.57K
+3.64%
Dr. Tomas Navratil
Dr. Tomas Navratil
Chief Development Officer
Chief Development Officer
49.04K
-3.13%
Mr. Marc A. Stapley
Mr. Marc A. Stapley
Independent Director
Independent Director
38.60K
+4.87%

Perguntas frequentes

Quem são os cinco principais acionistas de Glaukos Corp?

Os cinco principais acionistas de Glaukos Corp são: Mr. Thomas William Burns

Quantas instituições possuem ações da Glaukos Corp (GKOS)?

Em 2026Q1, 702 instituições possuíam ações da Glaukos Corp, com valor de mercado aproximado de 59.35M, representando 101.04% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -2784097.00.

Qual é a maior fonte de receita da Glaukos Corp?

Em 2026Q1, o segmento de negócios Glaucoma gerou a maior receita para Glaukos Corp, totalizando 421.07M e representando 82.98% da receita total.
KeyAI